Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

Peer review reports

Original Submission
21 Oct 2015	Submitted	Original manuscript
2 Dec 2015	Reviewed	Reviewer Report - Wataru Ichikawa
8 Dec 2015	Reviewed	Reviewer Report - Yves Becouarn
21 Dec 2015	Author responded	Author comments - Yung Sung Yeh
Resubmission - Version 2
21 Dec 2015	Submitted	Manuscript version 2
23 Dec 2015	Reviewed	Reviewer Report - Wataru Ichikawa
28 Dec 2015	Reviewed	Reviewer Report - Yves Becouarn
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
4 Jan 2016	Editorially accepted
25 Jan 2016	Article published	10.1186/s13063-016-1153-3

Back to article page